All In Biotech

Drug Trial Radar · NCT00421928

Tapentadol (CG5503)

A Randomized Double-Blind, Placebo- and Active-Control, Parallel-arm, Phase III Trial With Controlled Adjustment of Dose to Evaluate the Efficacy and Safety of CG5503 Extended-Release (ER) in Patients With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

Last checked: Nov 19, 2026Latest source record: Apr 18, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,030 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,030

Actual

Start

Jan 2007

Primary completion

Jul 2008

Study completion Dec 2008

Sponsor

Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
Grünenthal GmbH
First posted
Jan 15, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to evaluate the effectiveness (level of pain control) and safety of orally administered tapentadol (CG5503) Extended Release (ER) (base) at doses of 100-250 mg twice daily in patients with moderate to severe chronic pain due to osteoarthritis of the knee, in comparison with placebo and Oxycodone Controlled Release (CR).

Conditions

  • Osteoarthritis, Knee
  • Pain

Interventions

  • oxycodoneDrug

    10, 20, 30, 40, 50mg twice a day (BID) during 15 weeks

  • placeboDrug

    matching placebo twice a day (BID) during 15 weeks

  • tapentadol (CG5503)Drug

    50, 100, 150, 200, 250mg twice a day (BID) during 15 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12.Time frame: Baseline and 12 weeks (Primary endpoint is the average pain intensity score during the last week of the maintenance period).

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.